The Zygomycosis (Mucormycosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Zygomycosis (Mucormycosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Zygomycosis (Mucormycosis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Zygomycosis (Mucormycosis) and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Zygomycosis (Mucormycosis) by nine companies/universities/institutes. The top development phase for Zygomycosis (Mucormycosis) is preclinical with four drugs in that stage. The Zygomycosis (Mucormycosis) pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Zygomycosis (Mucormycosis) pipeline products market are: Alkem Laboratories, Scynexis and Biosergen.
The key targets in the Zygomycosis (Mucormycosis) pipeline products market include Ergosterol, Cell Membrane, and 1,3 Beta Glucan Synthase.
The key mechanisms of action in the Zygomycosis (Mucormycosis) pipeline product include Ergosterol Inhibitor with two drugs in Phase II. The Zygomycosis (Mucormycosis) pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Zygomycosis (Mucormycosis) pipeline products market including Small Molecule, and Synthetic Peptide.
Zygomycosis (Mucormycosis) overview
Mucormycosis is previously called as zygomycosis, is a serious but rare fungal infection caused by a group of molds called mucormycetes. This is characterized by tissue infarction and necrosis due to invasion of the vasculature by hyphae. It most commonly affects the sinuses or the lungs after inhaling fungal spores from the air
For a complete picture of Zygomycosis (Mucormycosis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
